Skip to main content
OpenTrials
Completed

NCT Number: NCT03506581

Dysfunctional Adiposity and Glucose Impairment

This is a large and comprehensively phenotyped cohort with fasting glycaemia where the predictive value of body composition and anthropometric measures of total and central fat distribution for postprandial carbohydrate intolerance are studied.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Subjects aged 18-70 years, who attended the Department of Endocrinology and Nutrition of the Clínica Universidad de Navarra from 2009-2014 for a check-up were offered to participate in the DICAMANO study. 853 subjects agreed to take part. Only those individuals with a normal fasting glucose level (≤5.5 mmol l-1) were analysed. Subjects with T2DM or severe renal, liver or thyroid dysfunction were excluded. Participants were instructed to temporarily discontinue for 48 hours any medication known to affect glucose or lipid metabolism. On the day of the study visit, each subject had a complete routine clinical assessment to evaluate the presence of cardiovascular, respiratory, renal or endocrine disorders. All patients underwent a 75-g OGTT with a concomitant anthropometric study, blood pressure monitoring and lipid profile analyses. They were classified by glucose tolerance on the basis of blood glucose levels according to ADA diagnostic criteria for T2DM (2017). Carbohydrate intolerance was defined as a 2-hOGTT glucose level ≥7.8 mmol l-1 (mg dl-1). Body composition, visceral adipose tissue, anthropometry study, OGTT-based parameters and cardiovascular risk factors are measured.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Fasting glucose level ≤ 5.5 mmol l-1
  • BMI ≥ 25

Exclusion criteria

  • Type 2 diabetes mellitus
  • Severe renal, liver or thyroid dysfunction

Treatment and study plan

Primary outcomes

  1. Body fat percentage and carbohydrate intolerance

    Time frame: Baseline

    Investigate whether body fat percentage estimated by air-displacement plethysmography (Bod-Pod®, Life Measurements, Concord, CA, USA) predicts postprandial carbohydrate intolerance early on in the metabolic dysregulation process.

    Body fat percentage (BF%) is calculated from body density by means of the Siri equation.

  2. Neck circumference as screening tool

    Time frame: Baseline

    Examine the predictive value of neck circumference as screening tool for the selection of patients who are most likely to benefit from an oral glucose tolerance test (OGTT)

Secondary outcomes

  1. Waist-to-hip ratio as screening tool

    Time frame: Baseline

    Examine the predictive value of waist-to-hip ratio as screening tool for the selection of patients who are most likely to benefit from an oral glucose tolerance test (OGTT). Waist-to-hip ratio was calculated as waist circumference divided by hip circumference. Waist circumference was measured at the midpoint between the iliac crest and the rib cage on the mid-axillary line, and hip circumference at the level of the greater trochanters was measured to the nearest millimetre using a flexible tape.

  2. Waist-to-height ratio as screening tool

    Time frame: Baseline

    Examine the predictive value of waist-to-height ratio as screening tool for the selection of patients who are most likely to benefit from an oral glucose tolerance test (OGTT). Waist-to-height ratio was calculated as waist circumference divided by height.

  3. BMI as screening tool

    Time frame: Baseline

    Examine the predictive value of body adiposity index (BMI) as screening tool for the selection of patients who are most likely to benefit from an oral glucose tolerance test (OGTT). BMI was calculated as weight in kilograms divided by height in meters squared.

  4. Body adiposity index as screening tool

    Time frame: Baseline

    Examine the predictive value of body adiposity index (BAI) ([hip circumference/height1.5]-18) as screening tool for the selection of patients who are most likely to benefit from an oral glucose tolerance test (OGTT).

  5. Central fat depot and carbohydrate intolerance

    Time frame: Baseline

    Investigate whether central fat depot predicts postprandial carbohydrate intolerance early on in the metabolic dysregulation process. Visceral and abdominal adiposity was quantified by the use of the abdominal bioelectrical impedance analysis device ViScan (Tanita AB-140, Tanita Corp., Tokyo, Japan).

  6. Central fat depot and cardiometabolic risk

    Time frame: Baseline

    Investigate whether a higher central fat depot is able to identify those individuals with higher inflammatory parameters (c-reactive protein, homocysteine and uric acid) and cardiovascular risk (higher rate of hypercholesterolemia, hypertension and/or obstructive sleep apnea).

    Body fat percentage (BF%) is calculated from body density by means of the Siri equation.

  7. Body fat percentage and cardiometabolic risk

    Time frame: Baseline

    Investigate whether a higher body fat percentage is able to identify those individuals with higher inflammatory parameters (c-reactive protein, homocysteine and uric acid) and cardiovascular risk (higher rate of hypercholesterolemia, hypertension and/or obstructive sleep apnea).

    Body fat percentage (BF%) is calculated from body density by means of the Siri equation.

  8. Prevalence of postprandial carbohydrate intolerance

    Time frame: Baseline

    Assess the prevalence of postprandial carbohydrate intolerance in individuals with normal fasting glycaemia

  9. Oral glucose tolerance test parameters and cardiometabolic profile

    Time frame: Baseline

    Verification of the utility of the two-hour OGTT glucose value to select those individuals with higher cardiometabolic risk (higher rate of hypercholesterolemia, hypertension and/or obstructive sleep apnea).

  10. Non-alcoholic fatty liver disease (NAFLD) and glucose dysregulation

    Time frame: Baseline

    Analyse the association between NAFLD and OGTT-based ß-cell function and insulin resistance in non-diabetic subjects.

  11. OGTT-based indices as screening tool of NAFLD

    Time frame: Baseline

    Examine whether OGTT-based ß-cell function and insulin resistance indices could be used as screening tools for the selection of patients who are most likely to benefit from a NAFLD-study.

  12. OGTT-derived glucose curve as screening tool of NAFLD

    Time frame: Baseline

    Examine whether the glucose response curve could be used as screening tool for the selection of patients who are most likely to benefit from a NAFLD-study.

Sponsors and collaborators

Lead sponsor

Clinica Universidad de Navarra, Universidad de Navarra

Other

Collaborators

  • Instituto de Salud Carlos III

Registry information

Official study title

Discovering Carbohydrate Metabolism Alterations in Normoglycemic Obese Patients Study

Acronym: DICAMANO

Important dates

Study start
2009
Primary completion
2014
Study completion
2016
First posted
Apr 24, 2018
Registry last updated
Apr 25, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.